Retrospective study on the characteristics and treatment of late-onset vitiligo

Yan Ling Kong¹, Vanessa Hui Ling Ching², Sai Yee Chuah¹, Tien Guan Thng¹,³
¹National Skin Centre, ²Yong Loo Lin School of Medicine, National University of Singapore, ³Skin Research Institute of Singapore, ASTAR, Singapore

Abstract
Background: Late-onset vitiligo, defined as being aged 50 years and above at the point of clinical onset, remains poorly characterized till now.
Aim: This study aims to describe the clinical characteristics and treatment response of patients with late-onset vitiligo.
Methods: We retrospectively reviewed the case records of all patients diagnosed with late-onset vitiligo, from January 1, 2010 to December 31, 2014. Information obtained included patient demographics, characteristics of vitiligo and treatment responses.
Results: Of the 3128 patients diagnosed with vitiligo over the 5-year period, 461 (14.7%) had late-onset disease. The study had more females (n = 260, 56.4%) than males, with an average onset age of 59.4 ± 7.4 years. Majority of patients were Chinese (n = 308, 66.8%) and 45 (9.8%) patients had an associated autoimmune disease. Focal vitiligo, defined as the localized presence of depigmented patches, was most common (n = 209, 45.3%). Treatment response was evaluated in 359 patients, of which 216 received monotherapy (topical creams: n = 210, 97.2%; phototherapy: n = 6, 2.8%) and 143 received both modalities. Fifty six (15.6%) patients received oral steroids. Patients who were treated with both topical creams and phototherapy yielded better clinical responses compared to those on monotherapy (P < 0.001) with 56.6% (n = 81) of them achieving good epidermal repigmentation, defined as >50% return of pigmentation compared to baseline (vs. n = 66, 30.6% in the monotherapy group). The choice of phototherapy (targeted, narrowband ultraviolet B or psoralen + ultraviolet A) did not significantly affect clinical response (P = 0.774).
Limitations: This study is limited by its retrospective nature, the nonstandardized documentation resulting in the inability to determine disease progression and associated metabolic comorbidities and also by the gradual loss to follow-up of patients.
Conclusion: Late-onset vitiligo is not uncommon and tends to be of the focal vitiligo subtype. Nonsegmented vitiligo is more prevalent than segmental vitiligo. Combination therapy with topical medications and phototherapy is superior to monotherapy.

Key words: Late-onset vitiligo, repigmentation, phototherapy, vitiligo treatment

Introduction
Vitiligo is a common acquired skin and mucosal disorder, characterized clinically by circumscribed white macules that enlarge and can potentially affect the entire skin. Its mechanism involves the progressive and selective destruction of melanocytes resulting in complete loss of pigmentation. While vitiligo is a relatively benign condition, it can pose dire psychosocial challenges to those affected by the disease.¹

Access this article online
Quick Response Code: Website: www.ijdvl.com
DOI: 10.4103/ijdvl.IJDVL_650_16

How to cite this article: Kong YL, Ching VH, Chuah SY, Thng TG. Retrospective study on the characteristics and treatment of late-onset vitiligo. Indian J Dermatol Venereol Leprol 2017;83:625.

Received: September, 2016. Accepted: February, 2017.
have chosen to define late-onset vitiligo as being aged 50 years and above at the time of clinical onset for the purpose of this study. To date, only two relatively small-scale studies have investigated the epidemiological and clinical features of late-onset vitiligo and both studies did not explore treatment efficacy in this subset of patients. This present study aims to describe the clinical characteristics and retrospectively determine treatment response of patients with late-onset vitiligo.

**Methods**

**Study population and data collection**

We carried out a retrospective study, approved by the Ethics Board (study reference E/15/696), at a tertiary care dermatological institution in Singapore. The profiles of all patients diagnosed with late-onset vitiligo, defined as being aged 50 years and above at the point of clinical onset, from January 1, 2010 to December 31, 2014 were reviewed. Electronic medical records were used to identify such cases. The diagnosis of vitiligo was made clinically by experienced dermatologists and for patients with uncertain diagnoses, investigations such as wood’s lamp examination and fungal skin scrapings were done to rule out common differentials such as tinea versicolor and pityriasis alba.

Information obtained included patient demographics such as the age of disease onset, their race, gender, Fitzpatrick skin type and the presence of personal history of other autoimmune diseases. Family history of vitiligo and/or other autoimmune conditions, defined as the presence of disease in either first- or second-degree relatives, was also ascertained. Vitiligo was classified broadly into segmental, nonsegmental as well as mixed disease as guided by the Vitiligo Global Issues Consensus Conference. Focal vitiligo, defined as the presence of depigmented patches located in a small area without a segmental distribution, was classified as a subtype of nonsegmental vitiligo in this study. The presence of associated phenomenon such as koebnerization, leukotrichia and halo nevi as well as the treatment received and the maximal clinical response achieved subsequently were also determined. Epidermal repigmentation responses were categorized as “poor,” corresponding to ≤50% repigmentation or “good,” corresponding to >50% repigmentation compared to baseline.

**Statistical analysis**

Descriptive statistics were used to summarize the demographics and clinical characteristics of the patients. Fisher’s exact test was used to compare therapeutic efficacy between treatment groups due to the presence of small group counts (<5) and also because it allows for the provision of exact statistics as opposed to Chi-square test. A \( P < 0.05 \) was considered statistically significant.

**Results**

During the study period, a total of 3128 patients were diagnosed with vitiligo at our center. Of these, 461 (14.7%) patients had late-onset disease and their clinical characteristics are detailed in Table 1. There were 260 (56.4%) females and 201 (43.6%) males with a female-to-male ratio of 1.3:1. The average age of onset was 59.4 ± 7.4 years. Our patients presented early in the disease course, at a median of 7 months (range = 0.3–240.0 months) after clinical onset. The majority of them were Chinese (\( n = 308, 66.8\% \)), followed by Indians (\( n = 91, 19.7\% \)). Most patients were of Fitzpatrick skin types III (\( n = 151, 32.8\% \)) and IV (\( n = 143, 31.0\% \)). Excluding the patients who defaulted after a single visit (\( n = 97 \)), the mean follow-up period was 21.8 ± 21.7 months. Forty-five (9.8%) of patients had a history of other autoimmune disease, the most common being thyroid disorders (\( n = 31, 6.7\% \)), followed by alopecia areata (\( n = 7, 1.5\% \)). Among the patients with thyroid disorders, eight patients were diagnosed only after screening for associated autoimmune diseases upon diagnosis of vitiligo. Family history of vitiligo (\( n = 25, 5.4\% \)) or other autoimmune conditions (\( n = 17, 3.7\% \)) was less common. The majority of patients had nonsegmental vitiligo (\( n = 436, 94.6\% \)), of which focal vitiligo (\( n = 209, 45.3\% \)) was the most common subtype. On the other hand, segmental vitiligo (\( n = 25, 5.4\% \)) was uncommon in our study. For those with data available (\( n = 391 \)), the average total body surface area involved was 4.8% ± 9.6%. The most commonly affected site was the face (\( n = 331, 71.8\% \)) followed by the extremities (\( n = 201, 43.6\% \)) and finally, the truncal area (\( n = 155, 33.6\% \)). The presence of halo nevi, koebnerization and poliosis were rare, each occurring in <5% of our study population.

Treatment response, which is detailed in Table 2, was evaluated in 359 patients, after excluding those who defaulted after a single visit (\( n = 97 \)), those who did not receive any treatment (\( n = 4 \)) as well as a patient with universal vitiligo who underwent depigmentation therapy. The two main treatment modalities were topical creams and phototherapy and a minority of patients with stable vitiligo also underwent surgical grafting. Two hundred and sixteen patients received monotherapy, either with topical creams (\( n = 210, 97.2\% \)) or phototherapy (\( n = 6, 2.8\% \)). The remaining 143 patients received combination therapy, of which 139 (97.2%) patients were treated with both topical creams and phototherapy. Four (2.8%) patients also underwent surgical grafting. Of the 353 patients who received topical creams, 104 (29.5%) patients were prescribed topical steroids only, 22 (6.2%) patients received calcineurin inhibitors only and 227 (64.3%) patients were treated with both. Phototherapy options included targeted light treatment for localized disease, involving <2% of the total body surface area, narrowband ultraviolet B for generalized disease and less commonly, topical psoralen + ultraviolet A for acral involvement. Among the 149 patients who received phototherapy, 137 (91.9%) of them were treated with 1 modality (narrowband ultraviolet B: \( n = 53, 35.6\% \); psoralen + ultraviolet A: \( n = 1, 0.7\% \); targeted: \( n = 83, 55.7\% \)). Only 12 (8.1%) patients were treated with more than one type of phototherapy. In addition, for patients who were deemed by the attending physician to have unstable or rapidly progressing disease (\( n = 56, 15.6\% \)), short courses of oral steroids were given for an average of 2.3 months (range = 0.5–4 months). No other steroid-sparing agents were used.

Overall, 147 (40.9%) of patients achieved good treatment response with the return of pigmentation to more than 50% of the affected sites. Among them, 26 (17.7%) patients received short courses of oral steroids. Combination therapy with topical creams and phototherapy with or without the addition of surgical grafting, yielded better clinical response with 56.6% (\( n = 81 \)) of patients achieving good epidermal repigmentation. In comparison, only 30.6% (\( n = 66 \)) of patients receiving monotherapy achieved good epidermal repigmentation [Table 2, \( P < 0.001 \)]. Among the patients receiving combination therapy, 32 (22.4%) patients received short courses of oral steroids as compared to 24 (11.1%) patients in the monotherapy group. However, the type of phototherapy (targeted, narrowband ultraviolet B or psoralen + ultraviolet A) that the patient underwent did not
Table 1: Clinical characteristics of patients with late-onset vitiligo

| Characteristic                               | Total patients (n=461) | 95% CI of mean or proportion |
|----------------------------------------------|------------------------|------------------------------|
| **Age at onset in years**                    |                        |                              |
| Mean±SD                                      | 59.4±7.4               | 58.7-60.0                    |
| Median (minimum–maximum)                     | 58.0 (50.0-87.0)       |                              |
| **Gender (%)**                               |                        |                              |
| Female                                       | 260 (56.4)             | 51.8-60.9                    |
| Male                                         | 201 (43.6)             | 39.1-48.2                    |
| **Race (%)**                                 |                        |                              |
| Chinese                                      | 308 (66.8)             | 62.4-71.0                    |
| Indians                                      | 91 (19.7)              | 16.3-23.6                    |
| Malay                                        | 28 (6.1)               | 4.2-8.7                      |
| Eurasians                                    | 4 (0.9)                | 0.3-2.3                      |
| Others                                       | 30 (6.5)               | 4.6-9.2                      |
| **Fitzpatrick skin type (%)**                |                        |                              |
| Type I                                       | 1 (0.2)                | 0.03-1.5                     |
| Type II                                      | 4 (0.9)                | 0.3-2.3                      |
| Type III                                     | 151 (32.8)             | 28.6-37.2                    |
| Type IV                                      | 143 (31.0)             | 26.9-35.4                    |
| Type V                                       | 78 (16.9)              | 13.8-20.6                    |
| Unknown                                      | 84 (18.2)              | 14.9-22.0                    |
| **Duration of disease before presentation in months** |               |                              |
| Mean±SD                                      | 16.5±27.3              | 14.0-19.0                    |
| Median (minimum–maximum)                     | 7.0 (0.3-240.0)        |                              |
| **Follow-up period in months**               |                        |                              |
| Mean±SD                                      | 21.8±21.7              | 19.6-24.1                    |
| Median (minimum–maximum)                     | 15.0 (1.0-132.0)       |                              |
| **Personal history of other autoimmune disease (%)** |               |                              |
| Thyroid disease                              | 31 (6.7)               | 4.8-9.4                      |
| Alopecia areata                              | 7 (1.5)                | 0.7-3.2                      |
| Rheumatological conditions                   | 6 (1.3)                | 0.6-0.3                      |
| Diabetes mellitus                            | 1 (0.2)                | 0.03-1.5                     |
| **Family history (%)**                       |                        |                              |
| Vitiligo                                     | 25 (5.4)               | 3.7-7.9                      |
| Other autoimmune disease                     | 17 (3.7)               | 2.3-5.9                      |
| **Type of vitiligo (%)**                     |                        |                              |
| Mixed                                        | 0                      | NA                           |
| Segmental                                    | 25 (5.4)               | 3.7-7.9                      |
| Nonsegmental (%)                             | 436 (94.6)             | 92.1-96.3                    |
| Generalized                                  | 182 (39.5)             | 35.1-44.0                    |
| Universal                                    | 2 (0.4)                | 0.1-1.7                      |
| Acrofacial                                   | 43 (9.3)               | 7.0-12.4                     |
| Focal                                        | 209 (45.3)             | 40.8-49.9                    |
| **Total body surface area involved (%)**     |                        |                              |
| Mean±SD                                      | 4.8±9.6                | 3.8-5.7                      |
| Median (minimum–maximum)                     | 2.0 (1.0-84.0)         |                              |
| **Affected sites (%)**                       |                        |                              |
| Face                                         | 331 (71.8)             | 67.5-75.7                    |
| Extremities                                  | 201 (43.6)             | 39.1-48.2                    |
| Trunk                                        | 155 (33.6)             | 29.4-38.1                    |
| Hands and feet (acral)                       | 137 (29.7)             | 25.7-34.1                    |
| Others (%)                                   | 27 (5.9)               | 4.0-8.4                      |
| Halo nevi                                    | 1 (0.2)                | 0.03-1.5                     |
| Koebnerization                               | 16 (3.5)               | 2.1-5.6                      |
| Leukotrichia                                 | 13 (2.8)               | 1.6-4.8                      |

SD: Standard deviation, CI: Confidence interval, NA: Not available
significantly affect clinical response [Table 2, \(P = 0.774\)]. All 4 patients who underwent surgical grafting had excellent results with 3 (75.0%) patients achieving more than 95% repigmentation on the grafted sites.

**Discussion**

Due to aging populations worldwide, greater importance is being placed on the understanding and management of diseases that afflict the elderly. At present, there is scarce data on late-onset vitiligo and hence, we decided to embark on this study. Table 3 summarizes the findings in the present study compared to previously published reports on late-onset vitiligo. Compared to earlier studies, there was a higher proportion of patients at our center who were diagnosed with late-onset disease.\(^6\,\,\,5\) This may be a reflection of Singapore’s aging population, where rising life expectancies mirror the falling birth rates.\(^1\) According to the 2015 Singapore Population Census, Chinese (74.3%) make up the majority of our multiracial population, followed by the Malays (13.3%) and the Indians (9.1%).\(^1\)

Interestingly, there was a significantly higher proportion of Indians with late-onset vitiligo compared to the racial distribution in Singapore. The result is consistent with previous studies reporting a higher prevalence of vitiligo in India which may be due to the apparent color contrast in individuals of darker skin type, causing them to seek medical treatment early.\(^1\)\(^2\)\(^3\) Of significance too is the lower prevalence of late-onset vitiligo in Malays compared to their racial distribution. This has been demonstrated in previous vitiligo studies done in multiethnic populations which may indicate a genetic protection against vitiligo in this subgroup.\(^1\)\(^4\)\(^5\)

Interestingly, 45.3% (\(n = 209\)) of our elderly patients presented with focal vitiligo. This differs from the two studies on late-onset vitiligo, in which generalized vitiligo vulgaris was more prevalent than focal vitiligo.\(^1\)\(^4\)\(^5\) In this study, we determined the clinical type of vitiligo based on the diagnosis at first presentation to our institution. Hence, some of the patients diagnosed with focal vitiligo could have evolved into generalized vitiligo vulgaris subsequently but were not captured in our data, thereby resulting in skewing of the data with a smaller-than-expected percentage of patients having vitiligo vulgaris. In addition, as focal vitiligo is known to respond to monotherapy if treated at early stage, the observation of better outcome after combination therapy in this study hints that patients with focal vitiligo may have progressed to generalized vitiligo vulgaris subsequently. Segmental vitiligo was uncommon in our study which concurs with the existing literature.\(^5\) Segmental vitiligo generally occurs at a younger age with 41.3% presenting before 10 years of age and forms a significantly large subgroup of childhood vitiligo.\(^16\) Among the patients with late-onset vitiligo locally, 9.8% (\(n = 45\)) had a personal history of other autoimmune conditions and 5.4% (\(n = 25\)) had a family history of vitiligo which are both lower than the figures reported in two late-onset vitiligo studies.\(^4\)\(^5\) The difference may be attributable to genetic heterogeneity in the different populations studied. While type I diabetes mellitus was previously reported as the most commonly associated autoimmune condition in late-onset vitiligo, thyroid disease and alopecia areata were more prevalent in our study population and only one patient had a history of type I diabetes.\(^4\)\(^5\) Interestingly, among the eight patients who were diagnosed with thyroid disorders only upon diagnosis of vitiligo, majority (\(n = 6, 75.0\%\)) had good repigmentation following monotherapy with topical treatment only. This suggests the importance of screening for associated autoimmune diseases and its aggressive treatment upon diagnosis of late-onset vitiligo.

Patients receiving a combination of topical treatment and phototherapy had better repigmentation results. Topical treatment was well tolerated but a minority of patients developed mild side effects of phototherapy. These included itching or a burning sensation which resolved on cessation of light treatment. The results

---

**Table 2: Treatment response of patients with late-onset vitiligo**

| Type of treatment | Total (\(n = 359\)) | Maximum response | Minimum response |
|-------------------|---------------------|------------------|-----------------|
|                   |                     | 0%-50% repigmentation (\(n = 212\)) | 51%-100% repigmentation (\(n = 147\)) | \(P\) |
|                   |                     | \(n (%)\) | 95% CI of proportion | \(n (%)\) | 95% CI of proportion |  
| Therapy           | 359                 | 212 (59.1) | 53.9-64.0 | 147 (40.9) | 36.0-46.1 |  
| Monotherapy       | 216                 | 150 (69.4) | 62.9-75.3 | 66 (30.6) | 24.7-37.1 | <0.001 |
| Combination therapy | 143               | 62 (43.4) | 35.4-51.6 | 81 (56.6) | 48.4-64.6 |  
| Monotherapy       |                      | 210 (69.5) | 62.9-75.4 | 64 (30.5) | 24.6-37.1 | 1.000 |
| Phototherapy alone| 6                   | 4 (66.7) | 23.6-92.8 | 2 (33.3) | 7.2-76.4 |  
| Combination therapy |                  | 139 (44.6) | 36.5-53.0 | 77 (55.4) | 47.0-63.5 | 0.133 |
| Topicals alone    | 4                   | 0         | NA       | 4 (100.0) | NA       |  
| Oral steroids     | 56                  | 30 (53.6) | 40.7-66.0 | 26 (46.4) | 34.0-59.3 |  
| Monotherapy       | 24                  | 13 (54.2) | 35.1-72.1 | 11 (45.8) | 27.9-64.9 | 1.000 |
| Combination therapy | 32                 | 17 (53.1) | 36.5-69.1 | 15 (46.9) | 30.9-63.6 |  
| Type of phototherapy | 149              | 66 (44.3) | 36.5-52.4 | 83 (55.7) | 47.6-63.5 |  
| NBUVB             | 53                  | 23 (43.4) | 30.6-57.1 | 30 (56.6) | 42.9-69.4 | 0.774 |
| NBUVB + targeted  | 11                  | 6 (54.5) | 25.5-80.8 | 5 (45.5) | 19.2-74.5 |  
| PUVA              | 1                   | 0         | NA       | 1 (100.0) | NA       |  
| PUVA + targeted   | 1                   | 1 (100.0) | NA       | 0         | NA       |  
| Targeted          | 83                  | 36 (43.4) | 33.0-54.3 | 47 (56.6) | 45.7-67.0 |  

CI: Confidence interval; NBUVB: Narrowband ultraviolet B; PUVA: Psoralen ultraviolet A; NA: Not available
Kong, et al. Late-onset vitiligo

Table 3: Comparison of features in the current study to previous studies on late-onset vitiligo

| Clinical characteristics                          | Current study | Dogra et al., 2004 | Esfandiarpour et al., 2012 |
|--------------------------------------------------|---------------|--------------------|---------------------------|
| Proportion with late-onset vitiligo* (%)         | 14.7          | 6.8                | 6.5                       |
| Number of patients                               | 461           | 182                | 54                        |
| Age at onset (mean, years)                       | 59.4          | 55.0               | 56.6                      |
| Age at presentation (mean, years)                | 60.8          | -                  | 60.0                      |
| Time to presentation (range, months)             | 1-240         | 1-120              | 1-240                     |
| Gender (%)                                       |               |                    |                           |
| Male                                             | 56.4          | 47.8               | 51.9                      |
| Female                                           | 43.6          | 52.2               | 48.1                      |
| Personal history of other autoimmune diseases    | 9.8           |                    | 18.5                      |
| Family history of vitiligo (%)                   | 5.4\(^1\)     | 15.9\(^1\)         | 27.8\(^1\)                |
| Type of vitiligo (%)                             |               |                    |                           |
| Mixed                                            | 0             | 0                  | 0                         |
| Segmental                                        | 5.4           | 4.4                | 3.7                       |
| Nonsegmental                                     | 94.6          | 95.5               | 96.4                      |
| Generalized                                      | 39.5          | 83.5               | 59.3                      |
| Universal                                        | 0.4           | 0.5                | 3.7                       |
| Acrofacial                                       | 9.3           | 3.8                | 20.4                      |
| Focal                                            | 45.3          | 5.5                | 13.0                      |
| Purem mucosal                                    | 0             | 2.2                | 0                         |
| Halo nevi                                        | 0.2           | 3.8                | 1.9                       |
| Koebnerization                                   | 3.5           | 79.6               | 14.8                      |
| Leukotrichia                                     | 2.8           | 77.8               | 47.3                      |

\(^1\)Compared to all patients diagnosed with vitiligo over the same time period. \(^2\)First through second-degree relatives, \(^3\)First through fourth-degree relatives

obtained suggest that phototherapy is well-tolerated and effective for the elderly patients with late-onset vitiligo and that clinicians should have a low threshold toward starting phototherapy in addition to topical treatment in this group of patients.

The major limitation of this study is its retrospective nature. A significant number of patients (n = 97, 27.0%) were also lost to follow-up. Due to the nonstandardized documentation by the attending doctors, information of disease progression could not be confirmed in some patients. Hence, we were unable to determine the number of patients with focal vitiligo who eventually evolved into generalized vitiligo vulgaris. Metabolic comorbidities commonly afflict the geriatric population, but because the presence of associated medical problems was not consistently documented, we were unable to study the association between metabolic disorders and late-onset vitiligo. In addition, the use of short courses of oral steroids in some patients could have affected the analysis of treatment response.

**Conclusion**

Late-onset vitiligo is not uncommon as shown in our population and constitutes 14.7% of our total number of vitiligo patients. Focal vitiligo is the most common clinical type at initial onset while segmental vitiligo is rare. Autoimmune disease was present in 9.8% of our late-onset vitiligo patients, with thyroid disorders and alopecia areata being most common. Late-onset vitiligo patients respond better to combination of topical medications and phototherapy and phototherapy is efficacious and well-tolerated in the treatment of patients with late-onset vitiligo.

**Acknowledgment**

We thank Miss. Virlynn Tan for assistance with statistical analysis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Lerner AB. Vitiligo. J Invest Dermatol 1959;32:285-310.
2. Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA Jr. Childhood vitiligo. J Am Acad Dermatol 1987;16:948-54.
3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015;386:74-84.
4. Dogra S, Parsad D, Handa S, Kanwar AJ. Late onset vitiligo: A study of 182 patients. Int J Dermatol 2005;44:193-6.
5. Esfandiarpour I, Farajzadeh S. Clinical characteristics of late onset vitiligo in an Iranian population. Dermatol Sin 2012;30:43-6.
6. Kanwar AJ, Mahajan R, Parsad D. Effect of age at onset on disease characteristics in vitiligo. J Cutan Med Surg 2013;17:253-8.
7. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012;25:E1-13.
8. Lommerts JE, Schilder Y, de Rie MA, Wolkerstorfer A, Bekkenk MW. Focal vitiligo: Long-term follow-up of 52 cases. J Eur Acad Dermatol Venereol 2006;20:1550-4.
9. Gan EY, Kong YL, Tan WD, Thng ST, Goh BK. Twelve-month and sixty-month outcomes of noncultured cellular grafting for vitiligo. J Am Acad Dermatol 2016;75:564-71.
10. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-81.
11. Wong WK. Population Trends 2015. Department of Statistics, Singapore. Available from: https://www.singstat.gov.sg. [Last accessed on 2016 Jul 23].
12. Behl PN, Bhatia RK 400 cases of vitiligo. A clinico-therapeutic
analysis. Indian J Dermatol 1972;17:51-6.
13. Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149-56.
14. Koh MJ, Mok ZR, Chong WS. Phototherapy for the treatment of vitiligo in Asian children. Pediatr Dermatol 2015;32:192-7.
15. Wong SM, Baba R. Quality of life among Malaysian patients with vitiligo. Int J Dermatol 2012;51:158-61.
16. Nicolaïdou E, Antoniou C, Miniati A, Lagogianni E, Matekovits A, Stratigos A, et al. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol 2012;66:954-8.